DE69424362D1 - Verwendung von Histamin-gamma-globulin zur Herstellung eines immunomodulierenden und antiinflammatorischen Agens - Google Patents

Verwendung von Histamin-gamma-globulin zur Herstellung eines immunomodulierenden und antiinflammatorischen Agens

Info

Publication number
DE69424362D1
DE69424362D1 DE69424362T DE69424362T DE69424362D1 DE 69424362 D1 DE69424362 D1 DE 69424362D1 DE 69424362 T DE69424362 T DE 69424362T DE 69424362 T DE69424362 T DE 69424362T DE 69424362 D1 DE69424362 D1 DE 69424362D1
Authority
DE
Germany
Prior art keywords
agent
diseases
pharmaceutical composition
histamine
globulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69424362T
Other languages
English (en)
Other versions
DE69424362T2 (de
Inventor
Haruo Yoshii
Yuriko Fukata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Zoki Pharmaceutical Co Ltd
Original Assignee
Nippon Zoki Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Zoki Pharmaceutical Co Ltd filed Critical Nippon Zoki Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE69424362D1 publication Critical patent/DE69424362D1/de
Publication of DE69424362T2 publication Critical patent/DE69424362T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69424362T 1993-08-09 1994-08-09 Verwendung von Histamin-gamma-globulin zur Herstellung eines immunomodulierenden und antiinflammatorischen Agens Expired - Fee Related DE69424362T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP21804393A JP3193205B2 (ja) 1993-08-09 1993-08-09 好酸球増多抑制剤

Publications (2)

Publication Number Publication Date
DE69424362D1 true DE69424362D1 (de) 2000-06-15
DE69424362T2 DE69424362T2 (de) 2000-10-19

Family

ID=16713756

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69424362T Expired - Fee Related DE69424362T2 (de) 1993-08-09 1994-08-09 Verwendung von Histamin-gamma-globulin zur Herstellung eines immunomodulierenden und antiinflammatorischen Agens

Country Status (9)

Country Link
US (1) US5780026A (de)
EP (1) EP0646376B1 (de)
JP (1) JP3193205B2 (de)
KR (1) KR100275174B1 (de)
CN (3) CN1127983C (de)
AT (1) ATE192655T1 (de)
DE (1) DE69424362T2 (de)
ES (1) ES2146240T3 (de)
TW (1) TW258664B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3193205B2 (ja) * 1993-08-09 2001-07-30 日本臓器製薬株式会社 好酸球増多抑制剤
US6566386B2 (en) 1993-08-09 2003-05-20 Nippon Zoki Pharmaceutical Co., Ltd. Immunomodulating and antiinflammatory agent
IT1278052B1 (it) * 1995-03-14 1997-11-17 Mendes Srl Uso delle immunoglobuline della classe g, in particolare delle immunoglobuline per uso endovenoso o per uso intramuscolare, per
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
JPH0959180A (ja) * 1995-08-11 1997-03-04 Nippon Zoki Pharmaceut Co Ltd 活性化免疫グロブリン
US6071942A (en) 1996-05-14 2000-06-06 Maxim Pharmaceuticals, Inc. Elevation of circulating blood histamine levels
US5961969A (en) * 1996-05-14 1999-10-05 Maxim Pharmaceuticals, Inc. Stable circulating histamine levels
JPH10212246A (ja) 1997-01-30 1998-08-11 Nippon Zoki Pharmaceut Co Ltd 経口投与用製剤
US7232830B2 (en) 1998-06-26 2007-06-19 Elaine A Delack Method for treatment of neurodegenerative diseases and effects of aging
JP2000143536A (ja) * 1998-11-13 2000-05-23 Nippon Zoki Pharmaceut Co Ltd 抗浮腫剤
JP2000143537A (ja) * 1998-11-13 2000-05-23 Nippon Zoki Pharmaceut Co Ltd 細胞接着分子発現抑制剤
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
DE19944122A1 (de) * 1999-09-15 2001-03-29 Wolfgang Loh Histamin-Immunglobulin-Komplexe zur Behandlung von entzündlichen Erkrankungen bei Säugetieren
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
US20090317357A1 (en) * 2003-02-24 2009-12-24 Lawrence Steinman Methods for treating or preventing autoimmune disease using histamine h1 receptor-blocking agents
CA2789262C (en) 2005-04-28 2016-10-04 Proteus Digital Health, Inc. Pharma-informatics system
EP2063905B1 (de) 2006-09-18 2014-07-30 Raptor Pharmaceutical Inc Behandlungen von lebererkrankungen durch verabreichung von konjugaten aus rezeptor-assoziierten proteinen
EP2142200B1 (de) * 2007-05-10 2012-05-16 Rajesh Shah Formulierung auf homöopathischer basis
PL2398500T3 (pl) 2009-02-20 2019-09-30 2-Bbb Medicines B.V. System dostarczania leków na bazie glutationu
KR101741629B1 (ko) 2009-05-06 2017-05-31 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5585526A (en) * 1978-12-23 1980-06-27 Nippon Zoki Pharmaceut Co Ltd Remedy for allergic disease
US4705685A (en) * 1982-05-17 1987-11-10 Mcmichael John Methods and materials for treatment of disease states involving immunological factors
US4704273A (en) * 1982-05-17 1987-11-03 Mcmichael John Methods and materials for treatment of rheumatoid arthritis
US4705687A (en) * 1985-06-17 1987-11-10 Ortho Pharmaceutical (Canada) Ltd. Treatment of autoimmune diseases such as rheumatoid arthritis with suppressor factor
US5244902A (en) * 1989-08-21 1993-09-14 Beth Israel Hospital Association Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
IT1237475B (it) * 1989-10-06 1993-06-07 Allergeni modificati chimicamente e procedimento per la loro preparazione
US5192773A (en) * 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
JP3193205B2 (ja) * 1993-08-09 2001-07-30 日本臓器製薬株式会社 好酸球増多抑制剤

Also Published As

Publication number Publication date
US5780026A (en) 1998-07-14
JPH0753406A (ja) 1995-02-28
CN1127983C (zh) 2003-11-19
TW258664B (de) 1995-10-01
ES2146240T3 (es) 2000-08-01
DE69424362T2 (de) 2000-10-19
EP0646376A1 (de) 1995-04-05
JP3193205B2 (ja) 2001-07-30
CN1471974A (zh) 2004-02-04
KR950005323A (ko) 1995-03-20
ATE192655T1 (de) 2000-05-15
CN1121430A (zh) 1996-05-01
KR100275174B1 (ko) 2000-12-15
EP0646376B1 (de) 2000-05-10
CN1471975A (zh) 2004-02-04

Similar Documents

Publication Publication Date Title
DE69424362D1 (de) Verwendung von Histamin-gamma-globulin zur Herstellung eines immunomodulierenden und antiinflammatorischen Agens
MY131458A (en) Pyrolopyrimidine compounds
NL300224I2 (nl) 3-Benzazepinzonen gesubstitueerd met een benzocyclobutyl- of indanylalkylaminoalkylgroep, bruikbaar voor de behandeling van cardiovasculaire aandoeningen.
FI931370A (fi) Kvaeve innehaollande analoger av icke-aromatiska heterocykliska foereningar med en fusionerad ring
EP0335901A4 (en) Methods and compositions for the treatment of non-ige-mediated diseases
IL107884A0 (en) Sulphonamides, their manufacture and pharmaceutical compositions containing them
FI950697A (fi) IL-4:n ja/tai IL-10:n uudet käytöt ja vasta-aineet niitä vastaan
MY111201A (en) New imidazopyridines
MA19951A1 (fr) Procede de preparation d'acides amines tricycliques ainsi que des acides amines bicycliques servant d'intermediaires et leur utilisation comme medicament
ES2157992T3 (es) Alcoxi-alquil-carbamatos de imidazo(1,2-a)piridinas.
HU9402933D0 (en) Neurotensine-receptor-active 1-naphtyl-pyrazol-3-carboxamides process for producing them and pharmaceutical compositions containing them as active components
AU4850290A (en) Substituted quinolinecarboxylic acids
IT1091051B (it) Procedimento per l'estrusione ad alta riduzione di metalli
HK1010340A1 (en) The manufacture of compositions for the treatment of cell proliferation disorders
AU586808B2 (en) Purine derivatives
ATE236615T1 (de) Pharmazeutische zubereitung zur oralen anwendung enthaltend einen histamin-immunoglobulin komplex
FR2672888B1 (fr) Nouvelles urees et thiourees, leur preparation et leur application en therapeutique.
FI97884B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 3,4-dihydroksi-2,5-dihydrofuranonien valmistamiseksi
EP0459176A3 (en) Oligophosphates with antiviral activity
EP0412941A3 (en) Phospholipids for the treatment of multiple sclerosis
GB2132620B (en) Novel 6a-methylprednisolone derivatives and their manufacture and use

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee